Healio presents a list of the most-read cardiology articles from 2019. Our readers were interested in sex differences and disparities in heart disease, the role of wearable devices in CV health, omega-3 fatty acids, results of the DAPA-HF trial and more.
VIDEO: Sex differences, barriers persist for women with heart disease
In this video exclusive, Martha Gulati, MD, MS, FACC, FAHA, division chief of cardiology at the University of Arizona College of Medicine – Phoenix, physician executive director for Banner University Medicine Heart Institute and editor in chief of ACC’s CardioSmart, discusses the importance of considering sex-specific risk factors for CVD. Watch here
Intermittent fasting may benefit in metabolic syndrome
Patients with metabolic syndrome who limited their eating to a 10-hour window in addition to statin and antihypertensive medications had reductions in weight, BP, HbA1c and atherogenic lipids, according to a study published in Cell Metabolism. Read more
Sleep duration may be predictive of cardiometabolic risk factors, cerebrovascular disease mortality
Sleep duration was found to be a significant predictor of cardiometabolic risk factors and cerebrovascular disease mortality as well as cancer mortality. Read more
Dog ownership may improve outcomes, reduce mortality risk after CV events
Now people may have another reason to love their dogs even more: Dog ownership was linked to improved outcomes after a major CV event and with a lower risk for death in the long term, according to two studies published in Circulation: Cardiovascular Quality and Outcomes. Read more
Wearable devices and the revolution of cardiology via continuous care, remote monitoring
Wearable technology, including wrist-worn smartwatches and fitness monitors, is no longer the “future” of medicine. The use of wearable technologies and the potential in cardiology has become an intense topic of discussion in recent years. Of particular interest this year was the release of the Apple Heart Study data at the American College of Cardiology Scientific Session in March. Read more
Vitamin D, fish oil fail to reduce first HF hospitalization risk
Interventions with vitamin D or omega-3 failed to reduce rates of first heart failure hospitalization in a large cohort of healthy adults, although researchers observed a benefit for recurrent HF hospitalization with fish oil supplementation, according to findings from an ancillary study of the VITAL trial presented at the American Heart Association Scientific Sessions. Read more
PARAGON-HF top-line results: sacubitril/valsartan for HFpEF misses primary endpoint
Novartis announced top-line results from the PARAGON-HF trial, which showed that the trial narrowly missed statistical significance for the primary endpoint in patients with HF with preserved ejection fraction who were treated with sacubitril/valsartan compared with valsartan alone. Read more
New trial data show mixed findings for omega-3s
The Cardiology Today March 2019 cover story tackles recent data on omega-3 supplementation, in supplement and prescription form. Read more
ISAR-REACT 5: Prasugrel superior to ticagrelor in patients with ACS, planned invasive evaluation
In patients with ACS, with or without ST-segment elevation, the rate of death, MI or stroke was significantly reduced at 1 year with prasugrel compared with ticagrelor, without an increase in major bleeding, according to a head-to-head comparison of both strategies. Read more
VIDEO: Deepak Bhatt, MD, MPH, highlights REDUCE-IT, treating beyond LDL lowering
In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, highlights the take-home messages from his keynote lecture at the American Society for Preventive Cardiology Congress on CVD Prevention, which focused on key discoveries from REDUCE-IT and other trials showing benefit of treating patients beyond LDL lowering. Watch more
DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes
In patients with HF, with and without diabetes, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy, according to anticipated results of the DAPA-HF trial. Read more
FDA: Risk for biotin interference with lab tests, troponin remains a concern
The FDA updated its safety communication to remind the public, health care providers, lab personnel and lab test developers that biotin, or vitamin B7, can significantly interfere with certain diagnostic tests and cause incorrect results that may go undetected. The FDA remains concerned, in particular, with the potential for false results for troponin, which could result in missed diagnoses for MI. Read more
AUGUSTUS: Dual therapy with apixaban, P2Y12 inhibitor safe in Afib patients post-ACS or PCI
New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation. Read more
AHA updates BP measurement standards
Advances in techniques to measure BP accurately are essential outside and in the office setting, according to a scientific statement published by the American Heart Association in Hypertension. Read more
AHA: Nearly half of all US adults have CVD
At least 48%, or 121.5 million, of all adults in the United States had some form of CVD from 2013 to 2016, according to the American Heart Association’s new Heart and Stroke Statistics. Read more
Healio presents a list of the most-read cardiology articles from 2019. Our readers were interested in sex differences and disparities in heart disease, the role of wearable devices in CV health, omega-3 fatty acids, results of the DAPA-HF trial and more.
VIDEO: Sex differences, barriers persist for women with heart disease
In this video exclusive, Martha Gulati, MD, MS, FACC, FAHA, division chief of cardiology at the University of Arizona College of Medicine – Phoenix, physician executive director for Banner University Medicine Heart Institute and editor in chief of ACC’s CardioSmart, discusses the importance of considering sex-specific risk factors for CVD. Watch here
Intermittent fasting may benefit in metabolic syndrome
Patients with metabolic syndrome who limited their eating to a 10-hour window in addition to statin and antihypertensive medications had reductions in weight, BP, HbA1c and atherogenic lipids, according to a study published in Cell Metabolism. Read more
Sleep duration may be predictive of cardiometabolic risk factors, cerebrovascular disease mortality
Sleep duration was found to be a significant predictor of cardiometabolic risk factors and cerebrovascular disease mortality as well as cancer mortality. Read more
Dog ownership may improve outcomes, reduce mortality risk after CV events
Now people may have another reason to love their dogs even more: Dog ownership was linked to improved outcomes after a major CV event and with a lower risk for death in the long term, according to two studies published in Circulation: Cardiovascular Quality and Outcomes. Read more
Wearable devices and the revolution of cardiology via continuous care, remote monitoring
Wearable technology, including wrist-worn smartwatches and fitness monitors, is no longer the “future” of medicine. The use of wearable technologies and the potential in cardiology has become an intense topic of discussion in recent years. Of particular interest this year was the release of the Apple Heart Study data at the American College of Cardiology Scientific Session in March. Read more
Vitamin D, fish oil fail to reduce first HF hospitalization risk
Interventions with vitamin D or omega-3 failed to reduce rates of first heart failure hospitalization in a large cohort of healthy adults, although researchers observed a benefit for recurrent HF hospitalization with fish oil supplementation, according to findings from an ancillary study of the VITAL trial presented at the American Heart Association Scientific Sessions. Read more
PAGE BREAK
PARAGON-HF top-line results: sacubitril/valsartan for HFpEF misses primary endpoint
Novartis announced top-line results from the PARAGON-HF trial, which showed that the trial narrowly missed statistical significance for the primary endpoint in patients with HF with preserved ejection fraction who were treated with sacubitril/valsartan compared with valsartan alone. Read more
New trial data show mixed findings for omega-3s
The Cardiology Today March 2019 cover story tackles recent data on omega-3 supplementation, in supplement and prescription form. Read more
ISAR-REACT 5: Prasugrel superior to ticagrelor in patients with ACS, planned invasive evaluation
In patients with ACS, with or without ST-segment elevation, the rate of death, MI or stroke was significantly reduced at 1 year with prasugrel compared with ticagrelor, without an increase in major bleeding, according to a head-to-head comparison of both strategies. Read more
VIDEO: Deepak Bhatt, MD, MPH, highlights REDUCE-IT, treating beyond LDL lowering
In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, highlights the take-home messages from his keynote lecture at the American Society for Preventive Cardiology Congress on CVD Prevention, which focused on key discoveries from REDUCE-IT and other trials showing benefit of treating patients beyond LDL lowering. Watch more
DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes
In patients with HF, with and without diabetes, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy, according to anticipated results of the DAPA-HF trial. Read more
FDA: Risk for biotin interference with lab tests, troponin remains a concern
The FDA updated its safety communication to remind the public, health care providers, lab personnel and lab test developers that biotin, or vitamin B7, can significantly interfere with certain diagnostic tests and cause incorrect results that may go undetected. The FDA remains concerned, in particular, with the potential for false results for troponin, which could result in missed diagnoses for MI. Read more
AUGUSTUS: Dual therapy with apixaban, P2Y12 inhibitor safe in Afib patients post-ACS or PCI
New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation. Read more
AHA updates BP measurement standards
Advances in techniques to measure BP accurately are essential outside and in the office setting, according to a scientific statement published by the American Heart Association in Hypertension. Read more
AHA: Nearly half of all US adults have CVD
At least 48%, or 121.5 million, of all adults in the United States had some form of CVD from 2013 to 2016, according to the American Heart Association’s new Heart and Stroke Statistics. Read more
"fish" - Google News
December 31, 2019 at 08:07PM
https://ift.tt/2ZFTF1c
Healio's most-read cardiology news of 2019: Sex disparities, fish oil, DAPA-HF and more - Healio
"fish" - Google News
https://ift.tt/35JkYuc
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
No comments:
Post a Comment